EXHIBIT 13.1

Exhibit 13.1

To the Shareholders of
Commonwealth Biotechnologies, Inc.

For the first time since our initial public offering in 1997, Commonwealth
Biotechnologies, Inc. ("CBI" or the "Company") posted positive cash flows from
operations of approximately $243,000. This improvement is primarily
attributable to management's rigorous control of expenses while working to
maintain the top-line revenues of the Company. For the year, costs of goods sold
decreased approximately $801,000 and selling, general and administrative costs
decreased approximately $537,000 compared to 2001, while at the same time
management was able to maintain Corporate productivity.

On the other hand, gross revenues in 2002 were essentially flat compared to
2001. Even though the entire sector struggled in 2002, CBI management is not
using this as an excuse. Our focus is clearly on improving our revenues while
still holding down expenses. To this end, the Company is now squarely focused in
three principal areas; bio-defense related contracts, comprehensive research
contracts, and clinical lab support. In bio-defense in particular, CBI has been
extremely successful, acting as both prime contractor and sub-contractor to
several Federal agencies. Our work for these agencies is of National importance
and is on the cutting edge of analytical sciences. In January 2003, CBI signed
nearly $1.3 million in bio-defense related contracts and numerous other high
dollar contracts are pending. CBI has found its niche in bio-defense and is able
to offer efficient, state-of-the-art analyses to our customers in a time and
cost competitive fashion. It is worth noting that CBI is the principal life
sciences subcontractor to two different defense industry partners on two
different major bio-defense programs.

CBI is also at the forefront of novel methods for detection and assay of viral
DNAs and other pathogens. Assay work for the presence of Norwalk virus done on
behalf of the Centers for Disease Control through the various State Public
Health Services increased dramatically concomitant with reports of cruise-ship
borne illness. We continue to receive patient samples from physicians around the
country who rely on our Herpes virus-testing platform for analysis of residual
DNA attributable to each of the individual herpes viruses. Our pathogen testing
services have increased with execution of contracts for testing of swipes of
routine mail delivery and CBI has been instrumental in helping develop rapid
methods for detecting the possible presence of hazardous biological agents,
including anthrax. More and more, industry partners are seeking CBI's input for
design and implementation of quality control protocols and product stability
testing.

In 2002, CBI completed a small private placement of equity to its principal
shareholder, some members of the Board of Directors and management. These funds
were reserved for increased marketing activities and for identification and
retention of a new executive who would direct strategic business development at
the Company. In October, CBI announced that Charles R. Waldridge assumed this
position and he has been steadily working towards bringing new comprehensive
research contracts to CBI principally from the private pharmaceutical sector.
Mr. Waldridge was formerly Director of Global Business Development, Life
Sciences Division, Johnson Controls, Inc. where he was responsible for
development of their corporate strategy for entry into the life sciences market.
During his tenure, he initiated and developed new partnership agreements with
major companies such as Pfizer, Amgen, Biogen, Merck and other global corporate
clients in the life sciences sector. At CBI, Mr. Waldridge is actively marketing
our core competencies to potential big pharma partners.

Page 1


At the 2002 Annual Meeting of Shareholders, CBI announced animal trials were
about to be initiated in which the efficacy of HepArrest(R) was to be tested
against a potential competitive pharmaceutical. Positive results from these
trials were certain to better position HepArrest(TM) for licensing to a third
party for its continued development. We are pleased to announce the overwhelming
success of these trials from a scientific standpoint which proved yet again the
viability of HepArrest as a potential human pharmaceutical. CBI continues to
negotiate a license for HepArrest's further development.

Also in 2002, CBI retained the services of Segerdahl and Company, Inc. to
explore possible strategic options of the Company. Segerdahl has been quite
active in meeting with potential interested parties and continues to seek
alternatives for the Company, which is directed towards enhancing shareholder
value.

Finally, two of our Board members resigned in 2002. Management would like to
recognize and thank Dr. Raymond H. Cypess and Mr. G. Everett Allen for their
hard work in helping to focus CBI's future.

Thank You for Your Continued Support

2002 was another difficult year for CBI stockholders and the liquidity of our
stock continues to be an issue. Management believes the Company is dramatically
undervalued at present and continues to work with Segerdahl and Company, Inc.,
retained in 2002 to explore our strategic options, to explore all possibilities
aimed at enhancing shareholder value.

Through it all, CBI's employees have shown a marked dedication to CBI's success
and have maintained and even increased their productivity. Our ability to
attract long-term customers and to sign high dollar contracts with existing
staff is testament to their abilities and fortitude. Thanks to one and all.

You are cordially invited to attend CBI's 2003 Annual Meeting of Shareholders on
May 15, 2003 at 11:00 a.m. at the Company's facility.

With best regards,


/s/ Richard J. Freer, Ph.D. /s/ Robert B. Harris, Ph.D.
- ------------------------------ ------------------------------
Richard J. Freer, Ph.D. Robert B. Harris, Ph.D.
Chairman of the Board, COO President, CEO


/s/ Thomas R. Reynolds /s/ James H. Brennan
- ------------------------------ ------------------------------
Thomas R. Reynolds James H. Brennan
Executive Vice-President, Controller
Science and Technology

CBI welcomes your calls and inquiries.

Phone: 800-735-9224
Fax: 804-648-2642
E-Mail: info@cbi-biotech.com
Web: www.cbi-biotech.com
Address: 601 Biotech Drive
Richmond, VA 23235

Page 2


Stockholder Matters
Market for Common Equity

The Company completed its initial public offering on October 28, 1997 at a price
per share of $6.00. Since that time, the common stock has traded on the NASDAQ
Market ("NASDAQ"). The following table sets forth the range of high and low
sales price per share of common stock for 2002:

Period High Stock Price Low Stock Price
------ ---------------- ---------------

1st Quarter, 2001 $4.75 $3.31
2nd Quarter, 2001 $7.32 $3.00
3rd Quarter, 2001 $4.95 $3.28
4th Quarter, 2001 $9.49 $2.50

1st Quarter, 2002 $2.97 $1.65
2nd Quarter, 2002 $1.99 $1.23
3rd Quarter, 2002 $1.40 $0.57
4th Quarter, 2002 $1.15 $0.37

On March 24, 2003, the last reported sales price for a share of the Company's
common stock on NASDAQ was $1.50. As of March 24, 2003, there were 39 holders
of record of the Company's common stock and 960 beneficial holders.

The Company has not paid any cash dividends on its common stock. The Company
intends to retain its earnings to finance the growth and development of its
business and does not expect to declare or pay dividends in the foreseeable
future. The declaration of dividends is within the discretion of the Company.
However, the Company's ability to pay dividends may be constrained by certain
provisions of its industrial revenue bond financing.

Selected Financial Data

Set forth below is selected financial data with respect to the Company for the
years ended December 31, 2002 and December 31, 2001, which has been derived from
the audited financial statements of the Company. The selected financial data set
forth below should be read in conjunction with "Management's Discussion and
Analysis of Financial Conditions and Results of Operation."

For the years Ended December 31,
--------------------------------------
2002 2001 2000
---------- ----------- -----------
Operational Data:

Revenues: $4,434,379 $ 4,786,087 $ 4,366,959
Net Loss $ (625,726) $(1,673,031) $ (921,916)
Loss per common and
common equivalent share $ (0.29) $ (0.81) $ (0.51)
Weighted average common
shares outstanding 2,194,029 2,076,164 2,076,164

Balance Sheet Data:
Total Current Assets $ 838,687 $ 817,046 $ 2,469,882
Total Assets $7,823,073 $ 8,348,718 $10,343,694
Total Current Liabilities $ 751,986 $ 803,638 $ 916,743
Total Liabilities $4,481,986 $ 4,693,949 $ 4,994,129
Total Stockholders equity $3,341,087 $ 3,654,769 $ 5,349,565

Page 3


MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF
OPERATIONS.

The following should be read in conjunction with "Selected Financial Data" and
the Company's Audited Financial Statements and Notes thereto included herein:

Going Concern

The financial statements have been prepared assuming the Company will continue
as a going concern. The Company incurred losses totaling $625,726 during the
year ended December 31, 2002 and has a history of losses that have resulted in
an accumulated deficit of $8,863,912 at December 31, 2002. In addition, the
Company has had negative cash flows in three out of the past six years. The
years in which the Company reached positive cash flows were years in which
equity offerings were completed.

Management has taken a number of steps to improve cash flow and liquidity. Since
2001, the Company has reduced personnel levels, curtailed research and
development expenses, reduced marketing expenditures, deferred directors fees
and a portion of officers' compensation. The Company has also reduced or delayed
expenditures on items that are not critical to operations. Primarily as a result
of these actions, the Company was able to reduce its operating loss for 2002 to
$340,701, as compared to $1,327,471 for 2001.

The cash position of the Company will again remain uncertain in 2003. However,
the Company will continue to address the immediate needs for cash and liquidity
through an aggressive approach on a number of fronts. As indicated previously,
in both 2002 and 2001, when confronted with static revenues and declining cash
reserves, management reduced staffing through layoffs and attrition and reduced
or eliminated non-production related expenditures. Fiscal practices have been
strictly enforced which restricts all material purchases to service on-going
work only and serve to minimize all material inventories. Management will
continue adhering to these policies for the foreseeable future.

There can be no assurance that any funds required during the next twelve months
or thereafter can be generated from operations or that if such required funds
are not internally generated that funds will be available from external sources,
such as debt or equity financing or other potential sources. However, in August
2002, the Company completed a private placement of 335,555 shares of common
stock at a purchase price of $.90 per share and warrants to purchase an
additional 83,889 shares of common stock. Net proceeds to the Company from this
private placement amounted to $247,544.

The lack of adequate cash resulting from the inability to generate cash flow
from operations or to raise capital from external sources would force the
Company to substantially curtail or cease operations and would, therefore, have
a material adverse effect on its business. The Company is actively exploring the
availability of varying financial and strategic transactions, which, if
consummated, would address the Company's need to improve its financial condition
and/or its operations.

There can be no assurance that any such required funds will be available on
attractive terms or that they will not have a significantly dilutive effect on
the Company's existing shareholders. To this end, the Company has retained the
services of Segerdahl and Company, Inc., of Milwaukee, Wisconsin, to explore its
strategic options with regard to continued operations.

Page 4


As a result of the above, there is substantial doubt about the Company's ability
to continue as a going concern. These financial statements do not include any
adjustments relating to the recoverability or classification of asset carrying
amounts or the amounts and classification of liabilities that may result should
the Company be unable to continue as a going concern.

The Company's independent auditors have included a paragraph emphasizing "going
concern" in their report on our 2002 financial statements. These financial
statements do not include any adjustments relating to the recoverability or
classification of asset carrying amounts or the amounts and classifications of
liabilities that may result should the Company be unable to continue as a going
concern.

Overview

The Company's revenues are derived principally from providing macromolecular
synthetic and analytical services to researchers in the biotechnology industry
or who are engaged in life sciences research in government or academic labs
throughout the world. Development of innovative technologies for biotechnology
requires sophisticated laboratory techniques and the Company provides these
services to customers on a contract basis. The Company's customers consist of
private companies, academic institutions and government agencies, all of which
use biological processes to develop products for health care, agricultural, and
other purposes.

The Company generally derives revenue from two types of customers: those who
require a discrete set of services (lab services), and those who contract with
the Company on an extended basis for performance of a variety of integrated
services (commercial contracts, drug development contracts, and government
contracts). The Company continues to grow its defense contract business and is
now actively engaged in all areas in bio-defense related work. The Company acts
as both prime and subcontractor for bio-defense related work.

More often than not, the Company's customers provide repeat business to the
Company. The Company views commercial, drug development, and government
contracts as the more important source of revenue. The Company has continued to
focus its efforts on identifying these customers. These contracts generally
range from a few months to more than a year. Revenues are generally recognized
as services are rendered or as products are delivered. In addition, revenue is
also recognized with performance-based installments payable over the contract as
milestones are achieved.

The Company also derives revenues from genetic identity and clinical services.
There has been a dramatic and constant increase in the number of private
paternity cases implemented at the Company and in the number of molecular
diagnostic assays performed. The Company designed and implemented molecular
diagnostic assays for the presence of DNA attributable to the various human
herpes viruses. This platform technology is being used to serve individual
patients across the country and in support of an ongoing clinical study with a
new anti-viral therapeutic. The Company has grown its molecular diagnostic
platform in several other critical areas and its services are being used in
support of still other ongoing clinical trials and in support of fundamental
research and development programs for its clients.

Critical Accounting Policies

The Company considers its critical accounting policies to be those related to
estimates, revenue recognition, accounts receivable, property and equipment,
income taxes, research and development, employee stock plans and fair value of
financial instruments. A detailed explanation of these policies can be found in
Note 1 to the audited financial statements.

Page 5


Results of Operations

Year Ended December 31, 2002 Compared to Year Ended December 31, 2001.

Revenues

Gross revenues decreased by $351,708 or 7.3% from $4,786,087 during the year
ended December 31, 2001 ("2001") to $4,434,379 during the year ended December
31, 2002 ("2002").

On April 30, 2001, the Company signed a patent license agreement with Applied
Biosystems Group of PE Corporation, New York ("Applied Biosystems"). This
license agreement granted Applied Biosystems a non-exclusive, worldwide,
perpetual, non-assignable license under the Patent. This enabled Applied
Biosystems to research, develop, make, have made, import, market, use, sell,
have sold, offer to sale, distribute, have distributed and otherwise exploit
products and services and to pass on to end user customers of Applied Biosystems
or its distributors the right to use such product and services. The Company
received licensing fees of $400,000 in the second quarter of 2001, of which
$200,000 was received in cash and the remaining $200,000 in product and service
credits. This impacted favorably on last year's financial statements. Excluding
this one-time license fee, gross revenues increased by $48,292 or 1.1% from
$4,386,087 during the 2001 Period to $4,434,379 during the 2002 Period.

The Company experiences fluctuations in all revenue categories. Continuation of
existing projects, or engagement for future projects is usually dependent upon
the customer's satisfaction with the scientific results provided in initial
phases of the scientific program. Continuation of existing projects or
engagement of future projects also often depends upon factors beyond the
Company's control, such as the timing of product development and
commercialization programs of the Company's customers. The Company is unable to
predict for more than a few months in advance the volume and dollar amount of
future projects. The combined impact of commencement and termination of research
contracts from several large customers and unpredictable fluctuations in revenue
for laboratory services can result in very large fluctuations in financial
performance.

Revenues from lab services increased by $163,622 or 24.8% from $659,733 during
2001 to $823,355 during 2002. Over the course of the year, the Company has
continued to see growth in one-time orders. The Company continues to view lab
services as a potential revenue source. However, the Company views commercial
and government projects as the more important source of revenue and has
continued to focus its efforts on identifying long-term customers.

Revenues realized from various commercial contracts decreased by $261,961 or
14.7%, from $1,785,730 during 2001 to $1,523,769 during 2002. This decrease is
primarily due to work being completed with four major clients. Of the $1,523,769
in commercial contracts, two major clients represented 21.5% and 13.7%,
respectively, of the revenue earned during 2002.

Revenues realized from various government contracts increased by $255,447 or
16.3%, from $1,568,115 during 2001 to $1,823,562 during 2002. This increase was
primarily due to work on three government projects during 2002. Revenues
recognized from the Illinois Institute of Technology Research Institute
("IITRI") subcontract were $720,096 during 2002. Of the $720,096, $94,741
represents revenue from the fourth year of the contract, which was awarded in
September 2002. Additional revenues to be recognized for the remainder of the
fourth year of the contract in 2003 are $392,383. Revenues recognized from the
second Government Sponsor for 2002 amounted to $719,471. This project is
expected to be completed in February 2003 with additional funds of approximately
$300,000 to be added to the project for the remainder of 2003.

Page 6


Revenues recognized from a third Government Sponsor for 2002 amounted to
$288,043. This project was completed in January 2003. Additional funds of
approximately $400,000 have been added to perform additional work in 2003.

Revenues realized from various genetic testing decreased by $78,931 or 37.0%,
from $213,212 during 2001 to $134,281 during 2002. This decrease is a direct
result of the cancellation of a major contract by a customer who chose to
continue the work internally and the cancellation of our marketing efforts due
to the cost cutting policy issued by management.

In 2001, under license from a third party, the Company implemented rapid and
novel techniques for analysis of patient samples for the presence of residual
DNA attributable to the various human herpes viruses.

Revenues realized from this and other genotyping services decreased by $45,280
or 56.8%, from $125,046 during 2001 to $79,766 during 2002. In order to attract
new patient work, the Company offers discounts to large clinical practices. In
addition, the Company must pay royalties on the technology used.

Revenues realized from license fees in 2002 were $4,000 as compared to $402,000
in 2001. As mentioned below, this decrease is a direct result of the one-time
license fee paid to the Company.

On April 30, 2001 the Company signed a patent license agreement (U.S. Patent No.
6,110,683 entitled "Automated DNA Sequencer Loading Dye Which Contains A Lane
Tracking Aid issued August 29, 2000) with Applied Biosystems Group, an Applera
Corporation, Foster City, CA. The Company received licensing fees of $400,000 of
which $200,000 was received in cash in the second quarter and the remaining
$200,000 in product and service credits. These credits were utilized in June and
the equipment is fully operational.

In November 2001, the Company signed a license agreement for the in vitro use of
HepArrest(TM) with MediRox AB, Linkoping, Sweden. This non-exclusive license
limits MediRox to the use of HepArrest in its own proprietary diagnostic
instruments and obligates MediRox to purchase HepArrest from the Company.
MediRox will pay the Company a $50,000 license fee and is buying HepArrest
exclusively from CBI. Depending on how fast MediRox can grow its in vitro
diagnostic market sales of HepArrest can become a contributing revenue source
for the Company.

Cost of Services

Cost of services consists primarily of materials, labor, subcontractor costs and
overhead. The cost of services, excluding research and development costs,
decreased by $792,057 or 19.4% from $4,081,832 during 2001 to $3,289,775 during
2002. The cost of services as a percentage of revenue was 74.2% and 85.3% during
2002 and 2001, respectively. This percentage decrease was primarily due to
reduction in costs in direct materials and expenditures in subcontractor costs
(see below.)

Direct labor costs decreased by $55,768, or 4.9%, from $1,139,871 during 2001 to
$1,084,103 during 2002. This decrease reflects the cost cutting measures taken
by management that included reduced staffing through layoffs and attrition.

The costs for direct materials decreased by $121,089, or 12.9%, from $947,706
during 2001, to $825,897 during 2002. This decrease is directly attributable to
more labor-intensive projects obtained by the Company.

Page 7


Subcontractor costs as of 2001 were $102,907. These costs incurred were from
subcontractors in the new drug development activity that was placed in operation
in 2001. There were virtually no subcontract costs in 2002.

Overhead cost consists of indirect labor, depreciation, freight charges, repairs
and miscellaneous supplies not directly related to a particular project. Total
overhead costs decreased by $520,528 or 27.9%, from $1,863,187 during 2001 to
$1,342,659 during 2002. This decrease is primarily due to the following: 1)
reduction of salaries that were charged to indirect labor, 2) management reduced
staffing through layoffs and attrition and reduced or eliminated production
related expenditures, 3) reduced maintenance costs on equipment, and 4)
elimination of amortization costs associated with the purchase of contracts in
Drug Development.

Research and Development

Research and development costs within the Company fall into two general
categories: grant-related research and development and in-house research and
development. These categories are distinguished by those performed in support of
government grant-sponsored programs, and those performed in the absence of such
grants which are funded from working capital. Total expenditures to perform
grant-related research activities decreased by $9,034, or 63.0%, from $14,348
during 2001 to $5,314 during 2002. This decrease is primarily due to the Company
redirecting its focus on long-term commercial contracts. There were no
expenditures made by the Company for in-house research activities. This decision
is primarily attributable to the reallocation of all personnel from internal
research and development efforts to focus on its core business in contract
research.

Sales, General and Administrative

Sales, general and administrative expenses ("SGA") consist primarily of
compensation and related costs for administrative, marketing and sales
personnel, facility expenditures, professional fees, consulting, taxes, and
depreciation. Total SGA costs decreased by $537,387, or 26.6%, from $2,017,378
during 2001 to $1,479,991 during 2002. As a percentage of revenue, these costs
were 33.4% and 42.2% during 2002 and 2001, respectively.

Total compensation and benefits decreased by $80,767 or 13.4% from $604,606
during 2001 to $523,839 during 2002. This decrease is attributable to the
reduction in administrative staff due to the cost cutting measures implemented
by management in 2001.

Facility costs decreased by $41,581 or 41.1% from $101,259 during 2001 to
$59,678 during 2002. This decrease is primarily due to the elimination of rent
paid for the offices of the drug development division. Depreciation expense
decreased by $45,873 or 31.6%, from $145,231 during 2001 to $99,358 during 2002.
This decrease is primarily due to the write-off of obsolete equipment in 2001.
Taxes and Licenses decreased by $24,650 or 19.6% from $125,522 during 2001 to
$100,872 during 2002. This decrease is primarily due to a rate reduction in
Business Taxes, sales taxes and personnel property taxes paid to the state and
county in Virginia. Office expenses decreased by $37,712 or 38.6%, from $97,630
during 2001 to $59,918 during 2002. This decrease is primarily due to across the
board cuts in all items associated with conducting business in the office. Other
costs increased by $105,973 or 59.7% from $177,626 during 2001 to $71,653 during
2002. This decrease is primarily due to the difference in bad debt write-offs in
2001 that did not happen in 2002.

Page 8


Marketing costs decreased by $215,616 or 64.5%, from $334,505 during 2001 to
$118,889 during 2002. Based on management's decision to control expenditures,
there was virtually no advertising done during the 2002 Period. Whereas during
the 2001 Period, the Company opted to increase its marketing exposure throughout
the marketplace with major increases in advertising and public relations.

Other Income (Expenses)

Interest income decreased by $68,034, or 89.0%, from $76,414 during 2001 to
$8,380 during 2002. This decrease is due to the lack of investment income.

Interest costs incurred by the Company during the 2002 and 2001 Period's
included 1) interest paid to financial institutions for loans made to the
Company; 2) interest paid for the Company's IRBs; and 3) amortization of costs
incurred as a consequence of the completion of the Company's IRB financing.
Interest expense increased by $10,281 or 3.6%, from $283,124 during 2001 to
$293,405 during 2002.

In 2001, the Company elected to write-off costs for a private placement that did
not materialize during the year. This one-time write-off amounted to $110,598.
The Company also elected to take a complete inventory on all lab equipment. It
was determined that certain items could no longer be used or repaired. The
one-time write-off for these obsolete equipment items amounted to $48,417. There
were no similar expenses written off in 2002.

Year Ended December 31, 2001 Compared to Year Ended December 31, 2000.

Revenues

Gross revenues increased by $419,128 or 9.6% from $ 4,366,959 during ended
December 31, 2000 ("2000") to $4,786,087 during the year ended December 31,2001
("2001").

The Company experiences fluctuations in all revenue categories. Continuation of
existing projects, or engagement for future projects is usually dependent upon
the customer's satisfaction with the scientific results provided in initial
phases of the scientific program. Continuation of existing projects or
engagement of future projects also often depends upon factors beyond the
Company's control, such as the timing of product development and
commercialization programs of the Company's customers. The Company is unable to
predict for more than a few months in advance the volume and dollar amount of
future projects. The combined impact of commencement and termination of research
contracts from several large customers and unpredictable fluctuations in revenue
for laboratory services can result in very large fluctuations in financial
performance.

Revenues realized from lab services decreased by $204,004 or 23.6% from $863,737
during 2000 to $659,733 during 2001. As mentioned in the overview section above,
the Company continues to view lab services as a potential revenue source.
However, the Company views commercial and government projects as the more
important source of revenue and has continued to focus its efforts on
identifying long-term contractual customers.

Revenues realized from various commercial contracts increased by $588,581 or
49.2%, from $1,197,149 during 2000 to $1,785,730 during 2001. Of the $1,785,730
in commercial contracts, two major clients represented 10.3% and 9.6%,
respectively, of the revenue earned during 2001. During 2001, the Company
performed work on ninety-five commercial customers compared to forty-five during
2000.

Page 9


Revenues realized from various government contracts decreased by $439,075 or
21.9%, from $2,007,190 during 2000 to $1,568,115 during 2001. This decrease was
primarily due to delay in the release of funds necessary to perform work for the
IITRI program during the fourth quarter. The hold-status placed by IITRI is due
to a delay in release of funds to IITRI by the Sponsor of the research program
which in turn, was due to a delay in release of funds to the Sponsor by
Congress. However, subsequent to year-end, some of the funds that were delayed
have been released to the Company and the remainder of the funds that were
delayed is expected to be released during the remainder of the first quarter of
2002. As funds are released, work is recommenced on the program objectives.

At present, revenues from Government contracts primarily consist of two major
projects. Work on a third Government project, awarded in September 2001, is just
now beginning, due to delays caused by the events of September 11th. This latter
contract is for $550,000 for the period September 2001 through August 2006. The
Sponsor has the option to increase this contract by $225,000. Revenues realized
as of December 31, 2001 are $6,700.

Revenues recognized from the IITRI subcontract were $1,024,030 during 2001. Of
these monies, $125,784 represents revenue from the third year of the contract,
which was awarded in September 2001. Additional revenues to be recognized for
the remainder of the third year of the contract in 2002 are $473,314. It is
anticipated that revenues for the fourth year of the contract, to be awarded in
September 2002 and continuing into 2003, will be $1,129,680.

Revenues recognized from the second Government Sponsor for the period August
2001 through December 2001 are $384,543. These monies represent the first
portion of the second year of this contract. Additional revenues to be
recognized for the remainder of the second year of this contract during 2002 are
$545,667.

Revenues realized from various genetic testing decreased by $71,635 or 25.1%,
from $284,847 during 2000 to $213,212 during 2001. This overall decrease is a
direct result of the cancellation of a major contract by a customer who chose to
continue the work internally. Revenues from individual paternity testing
increased by $97,705 or 121.1% from $80,727 during 2000 to $178,432 during 2001.
This is due to a dramatic and constant increase in the number of private
paternity cases during 2001.

In 2001, under license from a third party, the Company implemented rapid and
novel techniques for analysis of patient samples for the presence of residual
DNA attributable to the various human herpes viruses. Gross revenues for the
period May 2001 through December 2001 for performance of these assays was
$187,366. However, in order to attract new patient work, the Company offers
discounts to large clinical practices. In addition, the Company must pay
royalties on the technology used. Hence, total net revenue derived from this
particular clinical technology platform amounted to $125,046 during 2001. There
were no revenues derived from herpes virus testing in 2000.

On April 30, 2001 the Company signed a patent license agreement (U.S. Patent No.
6,110,683 entitled "Automated DNA Sequencer Loading Dye Which Contains A Lane
Tracking Aid issued August 29, 2000) with Applied Biosystems Group, an Applera
Corporation, Foster City, CA. The Company received licensing fees of $400,000 of
which $200,000 was received in cash in the second quarter and the remaining
$200,000 in product and service credits. These credits were utilized in June and
the equipment is fully operational.

Page 10


In November 2001, the Company signed a license agreement for the in vitro use of
HepArrest(TM) with MediRox AB, Linkoping, Sweden. This non-exclusive license
limits MediRox to the use of HepArrest in its own proprietary diagnostic
instruments and obligates MediRox to purchase HepArrest from the Company.
MediRox will pay the Company a $50,000 license fee and is buying HepArrest
exclusively from CBI. Depending on how fast MediRox can grow its in vitro
diagnostic market, sales of HepArrest can become a contributing revenue source
for the Company.

Cost of Services

Cost of services consists primarily of materials, labor, subcontractor costs and
overhead. The cost of services increased by $701,496 or 22.0%, from $3,182,758
during 2000 to $3,884,254 during 2001. The cost of services as a percentage of
revenue was 81.2% and 72.9% during 2001 and 2000, respectively. This percentage
increase was primarily due to additional expenditures in subcontractor costs
(see below.)

Labor costs increased by $233,859, or 25.8%, from $906,012 during 2000 to
$1,139,871 during 2001. This increase reflects additional hours being directly
charged to projects in lieu of overhead.

The costs for direct materials increased by $74,441, or 13.8%, from $538,143
during 2000, to $612,584 during 2001. These increased costs are attributable to
the increase of revenue generated by the Company.

Subcontractor costs as of 2001 were $102,907. These costs incurred were from
subcontractors in the new drug development activity that was placed in operation
in 2001. There were no subcontract costs in 2000.

Overhead cost consists of indirect labor, depreciation, freight charges, repairs
and miscellaneous supplies not directly related to a particular project. Total
overhead costs increased by $397,322 or 25.0%, from $1,589,061 during 2000 to
$1,986,383 during 2001. Increased costs were seen primarily in the following
major categories: 1) indirect labor, $87,394; 2) fringe benefits from increased
costs and additional personnel, $77,448; and 3) amortization costs of $183,047
from the acquisition of the Drug Development contracts in January 2001.

Research and Development

Research and development costs within the Company fall into two general
categories: grant-related research and development and in-house research and
development. These categories are distinguished by those performed in support of
government grant-sponsored programs, and those performed in the absence of such
grants which are funded from working capital. Total expenditures for these two
categories decreased by $135,194, or 90.4%, from $149,542 during 2000 to $14,348
during 2001.

Expenditures to perform grant-related research activities decreased by $70,821
or 100.0%, from $70,821 during 2000 to $0 during 2001. This decrease is
primarily due to the Company redirecting its focus on long-term commercial
contracts.

Expenditures made by the Company for in-house research activities decreased by
$64,373 or 81.8%, from $78,721 during 2000 to $14,348 during 2001. This decrease
is primarily attributable to the reallocation of personnel from internal
research and development efforts to focus on its core business in contract
research.

Page 11


Sales, General and Administrative

Sales, general and administrative expenses ("SGA") consist primarily of
compensation and related costs for administrative, marketing and sales
personnel, facility expenditures, professional fees, consulting, taxes, and
depreciation. Total SGA costs increased by $411,838, or 22.7%, from $1,817,466
during 2000 to $2,229,304 during 2001. As a percentage of revenue, these costs
were 46.6% and 41.6% during 2001 and 2000, respectively.

Increases in SGA expenses were seen in the following categories. Total
compensation and benefits increased by $279,058 or 40.9% from $394,348 during
2000 to $673,406 during 2001. These increases are attributable to new employees
who assist in the administrative support of the Company (who have since been
laid off or put on part-time status as of the third quarter, 2001), to increased
vacation time used by staff who accrued an additional vacation week because of
their length of tenure with the Company, and increased benefits costs associated
with the Company's major medical and dental plans.

Professional fees increased by $70,652, or 22.9%, from $309,013 during 2000 to
$379,665 during 2001. This increase is primarily due to fees paid to consultants
who were initially used by the Company in pursuit of its Drug Development
contracts. In addition, the Company opted to increase its coverage in personal
liability for both the corporate and drug development offices. Office Expenses
decreased by $54,412, or 35.8% from $151,772 during 2000 to $97,360 during 2001.
This reduction is a direct result of eliminating various items previously
purchased in prior periods which are no longer needed by the Company and to a
severe curtailment in office supply inventories.

Marketing Expenses increased by $185,522, or 124.5% from $148,983 during 2000 to
$334,505 during 2001. In the early part of the 2001 Period, the Company opted to
increase its marketing exposure with major increases in advertising and public
relations. This marketing effort has since been dramatically downscaled.

Other Income (Expenses)

Interest income increased by $33,631, or 53.1% from $63,348 during 2000 to
$96,979 during 2001. Interest income has been derived from investing the unused
portion of the restricted cash realized by the Company from the successful sale
(March, 1998) of Industrial Revenue Bonds (IRBs) for construction of the
Company's new facility. Interest income also increased due to the investing of
the proceeds received from the private placement on September 27, 2000.

Interest costs incurred by the Company during the 2000 and 2001 included: 1)
interest paid to financial institutions for loans made to the Company; 2)
interest paid for the Company's IRBs; and 3) amortization of costs incurred as a
consequence of the completion of the Company's IRB financing. Interest costs
decreased by $70,181 or 19.9% from $353,305 during 2000 to $283,124 during 2001.
This decrease is the result of payments on the principal balance of long-term
debt.

In addition, the Company elected to write-off costs for a private placement that
did not materialize during the year. This one-time write-off amounted to
$110,598. The Company also elected to take a complete inventory on all lab
equipment. It was determined that certain items could no longer be used or
repaired. The one-time write-off for these obsolete equipment items amounted to
$48,417.

Page 12


Liquidity and Capital Resources

For a discussion of the Company's current financial condition, please see the
section entitled "Going Concern". 2002 reflected an increase in cash of $242,912
from operating activities, as compared to a decrease of $819,811 from operating
activities during 2001. The increase in cash from operating activities during
2002 was primarily due to reduced staffing through layoffs and attrition and
reduced or eliminated non-production related expenditures. The decrease in cash
from operating activities during 2001 was primarily due to substantial
investments made by the Company in facility costs, personnel, equipment, and
marketing efforts.

Net working capital as of December 31, 2002 and December 31, 2001 was $86,701
and $13,408 respectively. This increase is a direct result of the cost cutting
measures taken by the Company.

The Company underwent an internal strategic review of its platform technologies
and an extensive independent examination of its fiscal policies and procedures.
The latter review confirmed that management acted appropriately to reduce
staffing through lay-offs and attrition and to reduce or eliminate all
non-production related expenditures. Fiscal practices have been strictly
enforced. Restrictions on all material purchases to service ongoing work only
and serve to minimize all material inventories have been curtailed. While
reductions in advertising and marketing negatively impact CBI's ability to
attract new work through the print media, expanded development and use of the
Company's web page (done with internal resources) combined with favorable
word-of-mouth and limited print advertising, continue to enhance CBI's exposure
to life sciences investigators throughout the world.

As a further result of the internal review, several scientific technology
platforms, which were not contributing to the overhead and profitability of the
Company, were eliminated while still others were re-priced. Management is keenly
aware of the need to continuously streamline its operations while maintaining
its competitive edge.

The Company's efforts continue to focus on long-term contractual projects
because they are more important source of revenues. Long-term projects generally
range in duration from a few months to several years.

In the fourth quarter of 1999, the Company was awarded a five-year subcontract
with the Illinois Institute of Technology Research Institute. The contract is
valued at approximately $8.5 million. During the third Quarter of 2002, the
fourth year of this contract was awarded to the Company and provided revenues of
approximately $94,741, of which $392,383 will be recognized during 2003.

The Company received an additional project in late September 2001 valued at
$887,000 of which $341,000 was recognized in the 2001 Period and the remaining
$546,000 was recognized during the 2002 Period. In early May 2002, the Company
was notified of a $252,000 increase to this existing bio-defense contract in
which the work commenced immediately. Through December 2002, the Company has
recognized $219,626 out of the $252,000. It is anticipated that additional
funding in 2003 will be awarded to the Company in March 2003. Approximate value
of additional funding is estimated at $300,000.

On February 28, 2002, the Company received $139,000 in advance for work to be
completed over a twenty-four month period. At present, the work scope for this
client will provide $417,000 in additional revenue to the Company. However,
management believes that the work scope will be expanded by the client as data
is collected and that the magnitude of the contract will be increased.

Page 13


On April 23, 2002, the Company announced that it engaged the services of
Segerdahl and Company, Inc., a registered broker-dealer, for the express purpose
of exploring the strategic options of CBI, with a focus on raising additional
equity capital, facilitating a re-capitalization, or the completion of any other
transaction which furthers the goals of profitability of the Company. The intent
of any such transaction would be to maximize shareholder value. In addition, any
such transaction would be subject to applicable securities rules, including the
possibility of shareholder approval. No agreements have been reached by the
Company as mediated by Segerdahl and Company, Inc.

Work on a third Government project was awarded in May 2002 for $267,000 and has
since been increased to $300,000. This project will be reviewed on an ongoing
basis and has the potential to increase its basis as needed. As of 2002, the
Company has recognized $288,042 from this project. In January 2003, additional
funding added to the project amounted to $400,000.

On August 30, 2002 the Company completed a private placement of 335,555 shares
of common stock at a purchase price of $.90 per share and warrants to purchase
an additional 83,889 shares of common stock. The purchase agreement requires the
Company to use its best efforts to prepare and file with the Securities and
Exchange Commission as soon as practicable a registration statement under the
Securities Act with respect to the resale of these securities. Net proceeds to
the Company from this private placement amounted to $247,544 and were to be used
to increase the marketing efforts of the Company.

Forward Looking Statements

Management has included herein certain forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933, as amended, and Section
21E of the Securities Exchange Act of 1934, as amended. When used, statements
that are not historical in nature, including the words "anticipated",
"estimate", "should", "expect", "believe", "intend", and similar expressions are
intended to identify forward-looking statements. Such statements are, by their
nature, subject to certain risks and uncertainties.

Among the factors that could cause the actual results to differ materially from
those projected are the following:

. business conditions and the general economy,

. the development and implementation of the Company's long-term business
goals,

. federal, state, and local regulatory environment,

. lack of demand for the Company's services,

. the ability of the Company's customers to perform services "in-house"
similar to those offered by the Company,

. potential cost containment by the Company's customers resulting in
fewer research and development projects,

. the Company's ability to receive accreditation to provide various
services, including, but not limited to paternity testing, and

. the Company's ability to hire and retain highly skilled employees.

Other risks, uncertainties, and factors that could cause actual results to
differ materially from those projected are detailed from time-to-time in reports
filed by the Company with the Securities and Exchange Commission, including
Forms 8-K, 10-QSB, and 10-KSB.

Page 14


Corporate Information

Corporate Office

Commonwealth Biotechnologies, Inc.
601 Biotech Drive
Richmond, VA 23235
Telephone: 800-735-9224; 804-648-3820
Fax: 804-648-2641
E-mail: info@cbi-biotech.com
Web site: www.cbi-biotech.com

General Counsel

Kaufman & Canoles, P.C.
Three James Center
12th Floor
1051 East Cary Street
Richmond, VA 23219

Patent Counsel

Burns Doan Swecker and Mathis, LLP
1737 King Street
Alexandria, VA 22314

Transfer Agent and Registrar

Computershare Trust Co.
350 Indiana St.
Golden, CO 80401

Independent Auditors

McGladrey and Pullen, LLP
7200 Glen Forest Drive, Suite 203
Richmond, VA 23226-3768

Page 15


Executive Officers and Board of Directors

Executive Officers

Richard J. Freer, Ph.D. Robert B. Harris, Ph.D.
Chairman of the Board, COO President, CEO

Thomas R. Reynolds James H. Brennan, MBA
Executive Vice President and Secretary Controller

Directors

Richard J. Freer, Ph.D. Robert B. Harris, Ph.D.
Chairman of the Board, COO President, CEO

Thomas R. Reynolds Samuel P. Sears, Jr.
Executive Vice President and Secretary Attorney-at-Law

L. McCarthy Downs III Donald A. McAfee, Ph.D.
Chairman of the Board Chief Technical Officer
Anderson & Strudwick Aderis Pharmaceuticals, Inc.
Investment Corporation

Page 16


McGladrey & Pullen
Certified Public Accountants

INDEPENDENT AUDITOR'S REPORT

To the Board of Directors and Stockholders
Commonwealth Biotechnologies, Inc.
Richmond, Virginia

We have audited the accompanying balance sheets of Commonwealth Biotechnologies,
Inc. as of December 31, 2002 and 2001 and the related statements of operations,
changes in stockholders' equity, and cash flows for the years then ended. These
financial statements are the responsibility of the Company's management. Our
responsibility is to express an opinion on these financial statements based on
our audits.

We conducted our audits in accordance with auditing standards generally accepted
in the United States of America. Those standards require that we plan and
perform the audit to obtain reasonable assurance about whether the financial
statements are free of material misstatement. An audit includes examining, on a
test basis, evidence supporting the amounts and disclosures in the financial
statements. An audit also includes assessing the accounting principles used and
significant estimates made by management, as well as evaluating the overall
financial statement presentation. We believe that our audits provide a
reasonable basis for our opinion.

In our opinion, the financial statements referred to above present fairly, in
all material respects, the financial position of Commonwealth Biotechnologies,
Inc. as of December 31, 2002 and 2001, and the results of its operations and its
cash flows for the years then ended, in conformity with accounting principles
generally accepted in the United States of America.

The accompanying financial statements have been prepared assuming the Company
will continue as a going concern. As discussed in Note 13 to the financial
statements, the Company's significant operating losses and negative cash flows
raise substantial doubt about its ability to continue as a going concern.
Management's plans regarding those matters are also described in Note 13. The
financial statements do not include any adjustments that might result from the
outcome of this uncertainty.

McGladrey & Pullen, LLP

Richmond, Virginia
February 18, 2003

McGladrey & Pullen, LLP is an
independent member firm of RSM
International, an affiliation
of independent accounting and
consulting firms.

Page 17


COMMONWEALTH BIOTECHNOLOGIES, INC.

BALANCE SHEETS
December 31, 2002 and 2001

ASSETS 2002 2001
- ------ ---------- -----------
Current Assets
Cash and cash equivalents $ 270,144 $ 116,151
Accounts receivable (Notes 3 and 7) 492,563 631,289
Prepaid expenses and other current assets 75,980 69,606
---------- ----------
Total current assets 838,687 817,046
---------- ----------

Property and Equipment, net (Notes 2, 3 and 4) 6,198,728 6,788,190

Other Assets
Bond issuance costs, less accumulated amortization
2002 $51,393; 2001 $40,649 217,205 227,949
Restricted cash (Note 4) 568,453 515,533
---------- ----------
Total other assets 785,658 743,482
---------- ----------
$7,823,073 $8,348,718
========== ==========

See Notes to Financial Statements.

Page 18